Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B

Maria Buti, Mar Riveiro-Barciela, Rafael Esteban

Research output: Contribution to journalReview articleResearchpeer-review

16 Citations (Scopus)


© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd Long-term treatment of chronic hepatitis B (CHB) with nucleos(t)ide analogues is often necessary to achieve durable viral suppression. Therefore, current guidelines recommend the most potent drugs with optimal resistance profiles. Entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are the first-line monotherapies for CHB. All of these drugs are highly effective in suppressing viral replication but with slightly different safety profiles. This review provides an overview of the long-term efficacy and safety data that have become available over the 10 years since ETV and TDF were first approved for the treatment of chronic hepatitis, and recent data on TAF in patients with CHB.
Original languageEnglish
Pages (from-to)84-89
JournalLiver International
Publication statusPublished - 1 Feb 2018


  • chronic hepatitis B
  • efficacy
  • entecavir
  • safety
  • tenofovir alafenamide
  • tenofovir disoproxil fumarate
  • treatment


Dive into the research topics of 'Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B'. Together they form a unique fingerprint.

Cite this